Payment overview · 2025
General Payments
$344.82
13 reported records · 7 companies
Healthcare provider profile · identity verified
Kenneth Phylex Jones, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORTH CHARLESTON, SC · NPI 1548344096
Verified facts
What the public records show
CMS Open Payments records show Kenneth Phylex Jones, M.D. received $344.82 in general payments during 2025 across 13 reported records.
Gilead Sciences, Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Biktarvy by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $97.36 | 28.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $81.93 | 23.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.79 | 14.7% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $40.62 | 11.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.39 | 9.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.80 | 6.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.93 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.82 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $97.36 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $81.93 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 671 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 643 | 199 |
| Metformin Hcl | Metformin Hcl | 325 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 296 | 97 |
| Losartan Potassium | Losartan Potassium | 296 | 93 |
| Diclofenac Sodium | Diclofenac Sodium | 279 | 81 |
| Omeprazole | Omeprazole | 275 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 64 |
| Simvastatin | Simvastatin | 225 | 67 |
| Gabapentin | Gabapentin | 202 | 74 |
| Lisinopril | Lisinopril | 188 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 42 |
| Famotidine | Famotidine | 165 | 40 |
| Potassium Chloride | Potassium Chloride | 161 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 159 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 135 | 39 |
| Carvedilol | Carvedilol | 134 | 45 |
| Furosemide | Furosemide | 131 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 117 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 41 |
| Ibuprofen | Ibuprofen | 110 | 34 |
| Meloxicam | Meloxicam | 110 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 25 |
| Montelukast Sodium | Montelukast Sodium | 104 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 41 |
| Allopurinol | Allopurinol | 98 | 32 |
| Ozempic | Semaglutide | 97 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 29 |
| Glipizide | Glipizide | 86 | 26 |
| Farxiga | Dapagliflozin Propanediol | 80 | 30 |
| Nifedipine Er | Nifedipine | 74 | 18 |
| Alendronate Sodium | Alendronate Sodium | 73 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 25 |
| Naproxen | Naproxen | 73 | 26 |
| Linzess | Linaclotide | 72 | 15 |
| Spironolactone | Spironolactone | 71 | 21 |
| Chlorthalidone | Chlorthalidone | 70 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 18 |
| Atenolol | Atenolol | 60 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 21 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Metformin Hcl Er | Metformin Hcl | 51 | 16 |
| Eliquis | Apixaban | 50 | 20 |
| Ondansetron Odt | Ondansetron | 50 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 19 |
| Azithromycin | Azithromycin | 47 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 16 |
| Jardiance | Empagliflozin | 43 | 16 |
| Clonidine Hcl | Clonidine Hcl | 42 | 16 |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Glipizide Er | Glipizide | 40 | 13 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Trazodone Hcl | Trazodone Hcl | 37 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | 12 |
| Glimepiride | Glimepiride | 32 | 13 |
| Entresto | Sacubitril/Valsartan | 31 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 12 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Theophylline Er | Theophylline Anhydrous | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Risperidone | Risperidone | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.82 · 13 records | Gilead Sciences, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, INGREZZA, LEQVIO, Ozempic, The Cologuard Plus Collection Kit, YUPELRI, Yeztugo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error